Nuclear Medicine

Accurate Diagnosis and Effective Cancer Therapy with Minimum Amount of Radiation

Nuclear Medicine of CBMC is divided into reception room, preparation room, injection room to inject radioactive isotope to the examinee, contamination inspection room to decontaminate any unfortunate radioactive contamination, waiting room, storage, disposal, and distribution room.

  • Gamma scan room 1: brain single photon emission computed tomography (SPECT), whole body bone scan
  • Gamma scan room 2: heart SPECT, bone SPECT, kidney scan scintigraphy including liver, gallbladder, spleen and gastrointestinal tract.
  • PET/CT (positron emission tomography/computed tomography) scan room 1/2: diagnosis of early cancer and metastasis, and visualization of brain metabolism
  • Thyroid uptake test room: thyroid function test

Latest PET/CT Model with the World's Largest Slice Number

As our new PET-CT has maximum 384 Slice CT, the amount of radiation exposed during the scan was greatly reduced up to 60% of that of the conventional equipments, minimizing the radioactive exposure on the human body. By visualizing body's glucose metabolism, PET/CT is commonly used to find malignant tumor and metastasis, to assess effect of cancer treatment, and to find recurrence of tumor.

PET/CT is also used for early diagnosis of Alzheimer's by analyzing the glucose metabolism in the brain. And through visualization of the dopamine transporter in the brain, it plays a pivotal role in diagnosis and determination of therapeutic effect of Parkinson's disease.

Introduction of VIZAMYL amyloid PET-CT

Our Flutemetamol PET-CT (F-18 flutemetamol Brain PET) has been introduced to diagnose Alzheimer's disease through color-coded brain images. It does not require fasting and takes only 20 minutes after 90-minute rest after intravenous injection of F-18-flutemetamol, allowing simple and easy examination for patients. The safety and efficacy of the examination was verified by the US FDA in 2013 and the European EMA in 2014. It was approved as an diagnostic radiotracer by the Korean government in August, 2015, and recognized as a new medical technology in February, 2016 and launched at our department for the first time in this country.